WEIR monoclonal antibody contract
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- Points of contact
-
- Joshua Holliday joshua.holliday@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration (FDA) is forecasting a new requirement contract for strain-specific influenza monoclonal antibodies to support the development of alternative potency assays for pandemic influenza vaccines. The contract is classified under the Analytical Laboratory Instrument Manufacturing NAICS code 334516, with an estimated solicitation release date of March 1, 2026, and a projected award date of May 1, 2026.
While specific award values and detailed performance requirements are not currently available, the contract will focus on developing critical monoclonal antibodies for pandemic influenza vaccine research. The primary point of contact for this opportunity is Joshua Holliday, who can be reached at joshua.holliday@fda.hhs.gov within the FDA organization. Potential vendors should note that this forecast does not indicate a specific set-aside status, suggesting the opportunity is open to a broad range of qualified laboratory and research-focused contractors.
Forecast text
WEIR monoclonal antibody contract. Strain specific influenza monoclonal antibodies are needed for development alternative potency assays for pandemic influenza vaccines.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast